Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Probes of interest in oncology, immunology, central nervous system diseases and rare diseases
Our chemical-based drug discovery approach has generated a set of potent, selective probes with promising drug-like properties that have not yet been developed. Many of these compounds are active at the sub-nanomolar level and demonstrate exceptional initial selectivity on kinases of major interest.
Oncodesign is committed to promoting partnership opportunities in the early stages of drug discovery. We are looking for partners with complementary skills to develop the therapeutic potential of these small cyclic molecules more quickly.
Our probes in development
